High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene

Cancer Research

Volumn 70, Issue 13, 2010, Pages 5379-5388

  Esposito, Francesco ^a   Tornincasa, Mara ^b   Chieffi, Paolo ^c   De Martino, Ivana ^b   Pierantoni, Giovanna Maria ^b   Fusco, Alfredo ^a,d  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Biotecnologie Avanzate Napoli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION;

EID: 77954360253     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4199     Document Type: TB

References (28)

1. Johnson KR, Lehn DA, Reeves R. Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 1989;9:2114-23. (Pubitemid 19117812)
2. Grosschedl R, Giese K, Pagel J. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet 1994;10:94-100. (Pubitemid 24075089)
3. Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-κB-dependent virus induction of the human IFN-β gene. Cell 1992;71:777-89.
4. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-4.
5. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGA1 gene during embryonic development. Oncogene 1996;13:2439-46. (Pubitemid 27026027)
6. Fusco A, Fedele M. Roles of the HMGA proteins in cancer. Nat Rev Cancer 2007;7:899-910.
7. Berlingieri MT, Manfioletti G, Santoro M, et al. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 1995;15:1545-53.
8. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, Fusco A. Thyroid cell transformation requires the expression of the HMG1 proteins. Oncogene 2002;21:2971-80. (Pubitemid 34522896)
9. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. Adenovirus-mediated suppression of the HMGI(Y) protein synthesis as a potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA 2000;97:4256-61. (Pubitemid 30226120)
10. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-61.
11. Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI (Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001;21:575-94. (Pubitemid 32037376)
12. Pierantoni GM, Rinaldo C, Esposito F, Mottolese M, Soddu S, Fusco A. High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ 2006;13:1554-63. (Pubitemid 44210358)
13. D'Orazi G, Cecchinelli B, Bruno T, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002;4:11-9. (Pubitemid 34071975)
14. Hofmann TG, Möller A, Sirma H, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002;4:1-10. (Pubitemid 34071974)
15. Pierantoni GM, Rinaldo C, Mottolese M, et al. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 2007;117:693-702. (Pubitemid 46348527)
16. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS. p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J Biol Chem 1999;274:15237-44. (Pubitemid 129518864)
17. Vousden KH, Lu X. Live or let die: the cell's response to p53 [review]. Nat Rev Cancer 2002;2:594-604. (Pubitemid 37328926)
18. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-ordeath switch [review]. Nat Rev Cancer 2002;2:647-56. (Pubitemid 37328916)
19. Monni O, Franssila K, Joensuu H, Knuutila S. BCL2 overexpression in diffuse large B-cell lymphoma [review]. Leuk Lymphoma 1999;34:45-52. (Pubitemid 29248658)
20. Wacheck V, Losert D, Günsberg P, et al. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 2003;13:393-400. (Pubitemid 38404824)
21. Reed JC, Meister L, Tanaka S, et al. Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 1991;51:6529-38.
22. Nathan B, Gusterson B, Jadayel D, et al, For the International (Ludwig) Breast Cancer Study Group. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. Ann Oncol 1994;5:409-14.
23. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview [review]. Apoptosis 2003;8:29-37.
24. Kassim SK, Ali HS, Sallam MM, et al. Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin Biochem 1999;32:333-8.
25. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 1994;145:1036-40. (Pubitemid 24345651)
26. Ciardiello F, Tortora G. Inhibition of bcl-2 as cancer therapy. Ann Oncol 2002;13:501-2.
27. Chiarugi V, Del Rosso M, Magnelli L. Brn-3a, a neuronal transcription factor of the POU gene family: indications for its involvement in cancer and angiogenesis [review]. Mol Biotechnol 2002;22:123-7.
28. Wiggins AK, Wei G, Doxakis E, et al. Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuron survival. J Cell Biol 2004;167:257-67.